|
Volumn 3, Issue SUPPL. 4, 1998, Pages 49-53
|
Early antiretroviral therapy: Rationale, protease inhibitor-sparing regimens and once daily dosing
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CD4 ANTIGEN;
DIDANOSINE;
EFAVIRENZ;
IMMUNOLOGIC FACTOR;
INDINAVIR;
LAMIVUDINE;
NELFINAVIR;
NEVIRAPINE;
PROTEINASE INHIBITOR;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SAQUINAVIR;
STAVUDINE;
UNCLASSIFIED DRUG;
VIRUS RNA;
ZALCITABINE;
ZIDOVUDINE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DISEASE COURSE;
DISEASE MARKER;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LYMPHOCYTE COUNT;
META ANALYSIS;
PRIORITY JOURNAL;
SYMPTOMATOLOGY;
VIRUS LOAD;
ANTI-HIV AGENTS;
HIV INFECTIONS;
HIV PROTEASE INHIBITORS;
HIV-1;
HUMANS;
PATIENT COMPLIANCE;
VIRAL LOAD;
|
EID: 0031797009
PISSN: 13596535
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (7)
|
References (5)
|